Cargando…

Factors associated with a bad functional prognosis in early inflammatory back pain: results from the DESIR cohort

BACKGROUND: Spondyloarthritis (SpA) is a heterogeneous disease with hardly predictable potential courses. We aimed at determining prognostic factors of bad functional outcome at 2 years in patients with early inflammatory back pain (IBP). METHODS: Data from patients included in the French multicentr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lukas, C, Dougados, M, Combe, B
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Spondyloarthritis
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4746580/ https://www.ncbi.nlm.nih.gov/pubmed/26870394 http://dx.doi.org/10.1136/rmdopen-2015-000204

Ejemplares similares

Spinal Radiographic Progression in Early Axial Spondyloarthritis: Five‐Year Results From the DESIR Cohort
por: Ramiro, Sofia, et al.
Publicado: (2019)

Costs of early spondyloarthritis: estimates from the first 3 years of the DESIR cohort
por: Harvard, Stephanie, et al.
Publicado: (2016)

5-year follow-up of spinal and sacroiliac MRI abnormalities in early axial spondyloarthritis: data from the DESIR cohort
por: Madari, Queeny, et al.
Publicado: (2020)

Imaging Outcomes for Axial Spondyloarthritis and Sensitivity to Change: A Five‐Year Analysis of the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2022)

Prevalence of degenerative changes and overlap with spondyloarthritis-associated lesions in the spine of patients from the DESIR cohort
por: de Bruin, Freek, et al.
Publicado: (2018)

Evaluation of the performances of ‘typical’ imaging abnormalities of axial spondyloarthritis: results of the cross-sectional ILOS-DESIR study
por: Molto, Anna, et al.
Publicado: (2019)

Evaluation of long-term TNFi effectiveness after a first switch in early axial spondyloarthritis considering time-varying prescription bias: an inverse-probability weighting analysis of the DESIR cohort
por: Pons, Marion, et al.
Publicado: (2022)

Can power Doppler ultrasound of the entheses help in classifying recent axial spondyloarthritis? Data from the DESIR cohort
por: Poulain, Cecile, et al.
Publicado: (2018)

Inflammation of the Sacroiliac Joints and Spine and Structural Changes on Magnetic Resonance Imaging in Axial Spondyloarthritis: Five‐Year Data From the DESIR Cohort
por: Sepriano, Alexandre, et al.
Publicado: (2021)

Determining factors related to impaired spinal and hip mobility in patients with axial spondyloarthritis: longitudinal results from the DESIR cohort
por: Carvalho, Pedro D, et al.
Publicado: (2020)

Sick leave in early axial spondyloarthritis: the role of clinical and socioeconomic factors. Five-year data from the DESIR cohort
por: Nikiphorou, Elena, et al.
Publicado: (2021)

Diagnostic accuracy of inflammatory back pain for axial spondyloarthritis in rheumatological care
por: Poddubnyy, Denis, et al.
Publicado: (2018)

Chronic back pain in first-degree relatives (FDRs) of patients with ankylosing spondylitis: predictive value of HLA-B27 and persistence of inflammatory back pain over time
por: Doughem, Karim, et al.
Publicado: (2020)

Relationships between ultrasound enthesitis, disease activity and axial radiographic structural changes in patients with early spondyloarthritis: data from DESIR cohort
por: Ruyssen-Witrand, Adeline, et al.
Publicado: (2017)

Prevalence and consequences of psoriasis in recent axial spondyloarthritis: an analysis of the DESIR cohort over 6 years
por: Lucasson, Florian, et al.
Publicado: (2022)

Serum inflammatory biomarkers fail to identify early axial spondyloarthritis: results from the SpondyloArthritis Caught Early (SPACE) cohort
por: Turina, Maureen C, et al.
Publicado: (2017)

Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA)
por: Dougados, Maxime, et al.
Publicado: (2023)

MRI for diagnosis of axial spondyloarthritis: major advance with critical limitations ‘Not everything that glisters is gold (standard)’
por: Lukas, Cédric, et al.
Publicado: (2018)

Clinical profile and treatment utilisation based on HLA-B*27 status in axial spondyloarthritis: results from ASAS-PerSpA study
por: Chaudhary, Haseeb, et al.
Publicado: (2023)

Does gender influence outcome measures similarly in patients with spondyloarthritis? Results from the ASAS-perSpA study
por: Benavent, Diego, et al.
Publicado: (2022)

Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST
por: Braun, Jürgen, et al.
Publicado: (2022)

Frequency of Axial Spondyloarthritis Diagnosis Among Patients Seen by US Rheumatologists for Evaluation of Chronic Back Pain
por: Deodhar, Atul, et al.
Publicado: (2016)

Effect of group-based physiotherapy on pain and depression in patients with axial spondyloarthritis and non-specific low back pain: data of 1-year follow-up
por: Hušáková, Markéta, et al.
Publicado: (2023)

Association between HLA-B27 and peripheral spondyloarthritis phenotype: results from the ASAS perSpA study
por: Arevalo Salaet, Marta, et al.
Publicado: (2022)

Sick leave and its predictors in ankylosing spondylitis: long-term results from the Outcome in Ankylosing Spondylitis International Study
por: Webers, Casper, et al.
Publicado: (2018)

No radiographic sacroiliitis progression was observed in patients with early spondyloarthritis at 6 years: results of the Esperanza multicentric prospective cohort
por: Fernández-Carballido, Cristina, et al.
Publicado: (2020)

Responsiveness of a simple RAPID-3-like index compared to disease-specific BASDAI and ASDAS indices in patients with axial spondyloarthritis
por: Castrejón, Isabel, et al.
Publicado: (2016)

Impact of disease activity outcome measures reporting in the medical records of patients with axial spondyloarthritis on the retention rates of biological treatment: the example of secukinumab use in daily practice in France
por: Dougados, Maxime, et al.
Publicado: (2022)

Maintenance of clinical remission in early axial spondyloarthritis following certolizumab pegol dose reduction
por: Landewé, Robert BM, et al.
Publicado: (2020)

Effect of Certolizumab Pegol Over Ninety-Six Weeks in Patients With Axial Spondyloarthritis: Results from a Phase III Randomized Trial
por: Sieper, J, et al.
Publicado: (2015)

Is it Useful to Repeat Magnetic Resonance Imaging of the Sacroiliac Joints After Three Months or One Year in the Diagnosis of Patients With Chronic Back Pain and Suspected Axial Spondyloarthritis?
por: Bakker, P. A. C., et al.
Publicado: (2019)

Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase IIb, randomised, double-blind, placebo-controlled, dose-ranging study
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Magnetic Resonance Imaging of the Sacroiliac Joints Indicating Sacroiliitis According to the Assessment of SpondyloArthritis international Society Definition in Healthy Individuals, Runners, and Women With Postpartum Back Pain
por: de Winter, Janneke, et al.
Publicado: (2018)

Lifestyle factors may modify the effect of disease activity on radiographic progression in patients with ankylosing spondylitis: a longitudinal analysis
por: Ramiro, Sofia, et al.
Publicado: (2015)

Characteristics and burden of disease in patients with radiographic and non-radiographic axial Spondyloarthritis: a comparison by systematic literature review and meta-analysis
por: López-Medina, Clementina, et al.
Publicado: (2019)

Spondyloarthritis in inflammatory bowel disease cohorts: systematic literature review and critical appraisal of study designs
por: Schwartzman, Monica, et al.
Publicado: (2022)

Efficacy and safety of bimekizumab in axial spondyloarthritis: results of two parallel phase 3 randomised controlled trials
por: van der Heijde, Désirée, et al.
Publicado: (2023)

Rate and Predisposing Factors for Sacroiliac Joint Radiographic Progression After a Two‐Year Follow‐up Period in Recent‐Onset Spondyloarthritis
por: Dougados, Maxime, et al.
Publicado: (2016)

Upadacitinib in active ankylosing spondylitis: results of the 2-year, double-blind, placebo-controlled SELECT-AXIS 1 study and open-label extension
por: van der Heijde, Désirée, et al.
Publicado: (2022)

Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One‐Year Results of a Double‐Blind, Placebo‐Controlled Study and Open‐Label Extension
por: Deodhar, Atul, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_i78qqugrlmd5qbbe81eidmpens